Exelixis, Inc.
- EXEL
- NASDAQ
- Biotechnology
- Oncology Drugs
- Cancer Therapeutics
$62.68
Today +0.72%Quote Oct 19, 2026, 08:00 PM UTC
+6.39%over the last month
Max drawdown −3.0%From 1-month high −1.0%3 months +12.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States.
Where the money comes from
Q2 2026 revenue $632.8M
- Net product revenues$573.0M90.5%
- License revenues$59.8M9.5%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
1,077
Market value
$15.75B
Quote Oct 19
Floor
$61.45
2.0% below price
Resistance
$63.05
0.6% above price
Price vs analyst targets
33 analysts
Lowest target
$49.00Highest target
$56.00
$49.00Highest target
$56.00
- Price $62.68
- Average target $52.33
- Analysts' target range
The price is above even the highest analyst target. Analysts' average target sits about 17% lower.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about EXELPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free